InterMune (ITMN) +89% premarket after EU's CHMP recommends its lung disease treatment Esbriet...
InterMune (ITMN) +89% premarket after EU's CHMP recommends its lung disease treatment Esbriet even earlier than expected. FDA rejected the drug in May, sending shares off a cliff. Esbriet would be the first effective treatment for the fatal disease idiopathic pulmonary fibrosis.
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs